Indeed, the presence of HER2 negative tumor cells in tumors classified clinically as HER2 positive and treated with HER2 targeting antibodies such as Trastuzumab is associated with de novo resistance to treatment and poor patient outcome [50,51,52]. The gene discussed is ERBB2; the disease is neoplasm.